Medicinal – Page 168

Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients—A Comprehensive Review

mycolabadmin

This review examines a serious but rare fungal infection called mucormycosis that affects the stomach and intestines. The infection most commonly occurs in patients with diabetes, those who have received organ transplants, or those in intensive care units. Diagnosis can be difficult because symptoms are non-specific, but prompt treatment with antifungal medications and surgery when possible significantly improves survival rates. Early recognition and rapid diagnosis are critical for patients to have the best outcomes.

Analysis of the correlation between the distribution of microorganisms carried by Coix seed and fungal toxins, and the biological control of aflatoxin

mycolabadmin

Coix seeds are popular in traditional Chinese medicine and food, but they can become contaminated with harmful fungi that produce toxins called mycotoxins. This study examined which fungi grow in Coix seeds from different regions and found that certain bacteria called Bacillus can effectively prevent dangerous mold from growing and producing toxins. By using these beneficial bacteria, producers can keep Coix seeds safer for people to consume as medicine or food.

Anti-Influenza Activity of Medicinal Material Extracts from Qinghai–Tibet Plateau

mycolabadmin

Researchers tested extracts from traditional Tibetan medicinal plants, mushrooms, and lichens to see if they could fight influenza virus. They found that seven out of nine extracts could reduce influenza virus infection in laboratory cells, with a mushroom extract called Armillaria luteo-virens showing particularly strong antiviral effects. These results suggest that traditional medicinal materials from the Qinghai–Tibetan plateau could be valuable sources for developing new flu treatments that might work better against drug-resistant flu strains.

Vesicle inhibition reduces Candida biofilm resistance

mycolabadmin

Researchers found that common FDA-approved drugs designed to block vesicle production in human cells can also reduce the protective matrix that Candida fungus builds around itself in biofilms. By combining these vesicle-blocking drugs with the antifungal fluconazole, the scientists were able to kill biofilm-forming Candida more effectively than either treatment alone. This discovery suggests a new approach to treating stubborn fungal infections on medical devices like catheters, potentially eliminating the need to surgically remove infected equipment.

Monoclonal Antibodies Can Aid in the Culture-Based Detection and Differentiation of Mucorales Fungi—The Flesh-Eating Pathogens Apophysomyces and Saksenaea as an Exemplar

mycolabadmin

Researchers developed a new diagnostic tool using specially designed antibodies to quickly identify dangerous flesh-eating fungi (Apophysomyces and Saksenaea) that cause severe infections. These fungi are particularly difficult to diagnose because they don’t produce spores on standard laboratory cultures. The new test can identify these pathogens in just 24-48 hours, much faster than traditional methods, which is critical since these infections progress rapidly and require immediate treatment. This advancement is especially important for hospitals in developing countries where expensive diagnostic equipment is unavailable.

Growth Propagation of Liquid Spawn on Non-Woven Hemp Mats to Inform Digital Biofabrication of Mycelium-Based Composites

mycolabadmin

Researchers developed a method to grow mushroom mycelium (fungal threads) in liquid form and apply it to hemp mats to create sustainable building materials. By testing different growth conditions and concentrations, they found ways to control how fast the mycelium spreads and covers the surface. This liquid-based approach offers advantages over traditional methods because it allows for more precise application and better control of material properties.

Safety and Efficacy of a 48-Month Efinaconazole 10% Solution Treatment/Maintenance Regimen: 24-Month Daily Use Followed by 24-Month Intermittent Use

mycolabadmin

Researchers studied a 4-year treatment plan for toenail fungal infections using efinaconazole, an antifungal solution applied daily for 2 years, then 2-3 times weekly for another 2 years. The treatment was safe and effective, with all patients who achieved a cure maintaining it through the maintenance phase, and even some non-cured patients improving further. The study included many elderly patients, showing the treatment is safe across all age groups and could help prevent infection relapse.

Diagnostic performance of Aspergillus-specific immunoglobulin G immunochromatographic and enzyme-linked immunosorbent assay testing in chronic pulmonary aspergillosis: comparative analysis across subtypes and influencing factors

mycolabadmin

Chronic pulmonary aspergillosis (CPA) is a serious fungal lung infection that primarily affects people with existing lung conditions. This study compared two methods to detect the disease: a fast, portable test (ICT) and a traditional laboratory test (ELISA). The faster ICT test was more accurate overall and can provide results quickly in areas without advanced laboratory facilities. However, patients already taking antifungal medications had lower test accuracy with both methods.

Neonatal Invasive Candidiasis: Current Concepts

mycolabadmin

Serious fungal infections (candidiasis) in newborns have become increasingly difficult to treat, especially in developing countries. The types of fungi causing these infections have changed dramatically, with many now resisting the standard fluconazole treatment. Modern medical care, like proper handwashing, environmental cleaning, and careful line care, is actually more effective at preventing these infections than giving preventive antifungal drugs. Healthcare providers need better tools for quickly identifying which fungal species is causing infection and which drugs will work against it.

Antimicrobial and antiparasitic potential of lupeol: antifungal effect on the Candida parapsilosis species complex and nematicidal activity against Caenorhabditis elegans

mycolabadmin

Researchers tested a natural compound called lupeol against disease-causing yeasts and parasitic worms. Lupeol successfully killed or inhibited the growth of Candida yeast species that are becoming resistant to current medications. The compound also showed strong activity against parasitic roundworms. This discovery suggests lupeol could be developed as a new treatment option for fungal and parasitic infections.

Research Topic: Medicinal